Although we don't believe intiming the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ...

When perusing the biotech sector, investors have more than 300 publicly traded companies on reputable exchanges that they can choose from. It's almost overwhelming, and it can make finding a company ...

PRINCETON, N.J.--(BUSINESS WIRE)-- Advaxis, Inc., (OTCBB: ADXS) ("Advaxis" or the "Company"), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, ...

Add Yahoo as a preferred source to see more of our stories on Google. By Vidya L Nathan (Reuters) - Advaxis Inc said its experimental cancer vaccine was found more effective in improving survival ...

Advaxis Inc., a Princeton biotech specializing in drugs treating cancer and infectious diseases, today named Daniel J. O’Connor as CEO, replacing Thomas Moore, who will continue to serve on the board ...

Women suffering from breast cancer. The two diseases may appear unrelated, but the Princeton-based biotech company Advaxis Inc. is eager to exploit the connection: Dogs with bone cancer express the ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in ...

What: After reporting intriguing data for its cancer therapy in dogs that could have implications for human cancer patients, shares in Advaxis, (ADXS +0.00%) are rallying 15% at 2:00 p.m. EST Monday.

We are just a few weeks into the year, and already shares of Advaxis ( ADXS) are up by more than 60%. But that's nothing. The shares have fully quadrupled since their November lows. Advaxis stock has ...

MONMOUTH JUNCTION, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy ...

PRINCETON, N.J.--(BUSINESS WIRE)-- Advaxis, Inc., (OTCBB:ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced today that it has secured ...

MONMOUTH JUNCTION, N.J., June 29, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy ...